75914-62-4

Basic information

• Product Name: 6-AMINO-1-CYCLOPROPYLPYRIMIDINE-2,4(1H,3H)-DIONE
• Synonyms: 6-AMINO-1-CYCLOPROPYLPYRIMIDINE-2,4(1H,3H)-DIONE;6-amino-1-cyclopropyl-pyrimidine-2,4-dione;6-amino-1-cyclopropylpyrimidine-2,4-dione;6-amino-1-cyclopropyl-pyrimidine-2,4-quinone;ZINC04218892
• CAS NO: 75914-62-4
• Molecular Formula: C7H9N3O2
• Molecular Weight: 167.17
• Mol File: 75914-62-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-AMINO-1-CYCLOPROPYLPYRIMIDINE-2,4(1H,3H)-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-AMINO-1-CYCLOPROPYLPYRIMIDINE-2,4(1H,3H)-DIONE(75914-62-4)
• EPA Substance Registry System: 6-AMINO-1-CYCLOPROPYLPYRIMIDINE-2,4(1H,3H)-DIONE(75914-62-4)

Safety Data

• Hazardous Substances Data: 75914-62-4(Hazardous Substances Data)

Upstream product

• 19757-64-3 1-cyclopropylurea 
• 372-09-8 cyanoacetic acid 
• 105-56-6 ethyl 2-cyanoacetate 
• 61600-96-2 1-cyanoacetyl-3-cyclopropylurea 

Downstream Products

• 75914-65-7 3-cyclopropyl-3,7-dihydro-1H-purine-2,6-dione 

Relevant articles and documents

Preparation of targeted eEF2K degradation agent and application of targeted eEF2K degradation agent in breast cancer prevention

The invention relates to preparation of a degradation agent targeting eEF2K and application of the degradation agent in breast cancer prevention, and belongs to the technical field of antitumor pharmacy. The technical problem to be solved by the invention is to provide a compound used as an eEF2K degradation agent. The compound comprises a compound product as shown in a specification in the invention or a pharmaceutically acceptable salt thereof. The compound product or the pharmaceutically acceptable salt thereof has activity of degrading eEF2K protein, can be used as a degradation agent of eEF2K, and can induce apoptosis of tumor cells so as to play a role in resisting breast cancer. The compound is preferably an anti-breast cancer compound, and is characterized by being a compound capable of degrading eEF2K protein.

Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals

Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals A compound of the formula STR1 where R1 and R3 are identical or different and at least one of the radicals R1 and R3 is a radical of the formula XI STR2 in which E is a covalent bond or a (C1 -C5)-alkyl, are suitable for the production of pharmaceuticals for the treatment of muscular atrophy, cachexia, muscular dystrophy, sepsis, septic shock, endotoxic shock, systemic inflammation response syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pneumonia, pulmonary sarcoidosis, reperfusion damage, scar formation, inflammation of the bowel and ulcerative colitis, as a result of infections, acquired immune deficiency syndrome, cancer, trauma and other disorders having increased protein loss, peripheral circulatory disorders, disorders having altered leucocyte adhesion, and also disorders which are accompanied by an increased or unregulated tumor necrosis factor production such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic disorders.